TY - JOUR
T1 - Screening colonoscopy
T2 - Has the time come?
AU - Lieberman, D.
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 1993
Y1 - 1993
N2 - Although current screening with flexible sigmoidoscopy and fetal occult blood test likely reduce colon cancer mortality, it is costly and probably not as effective as one-time screening with colonoscopy for detecting and preventing cancer, as well as risk stratification for further testing and surveillance. Ideal screening would target sensitive tests at high-risk individuals. It is possible that the identification of genetic or biologic markers in the future will enable us to target screening at high-risk individuals with precision.
AB - Although current screening with flexible sigmoidoscopy and fetal occult blood test likely reduce colon cancer mortality, it is costly and probably not as effective as one-time screening with colonoscopy for detecting and preventing cancer, as well as risk stratification for further testing and surveillance. Ideal screening would target sensitive tests at high-risk individuals. It is possible that the identification of genetic or biologic markers in the future will enable us to target screening at high-risk individuals with precision.
UR - http://www.scopus.com/inward/record.url?scp=0027435942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027435942&partnerID=8YFLogxK
U2 - 10.1016/s1052-5157(18)30539-7
DO - 10.1016/s1052-5157(18)30539-7
M3 - Review article
AN - SCOPUS:0027435942
VL - 3
SP - 673
EP - 682
JO - Gastrointestinal Endoscopy Clinics of North America
JF - Gastrointestinal Endoscopy Clinics of North America
SN - 1052-5157
IS - 4
ER -